In recent years, SBS management has taken a new turn with the advent of GLP-2 analogues that are now considered the first-line treatment for SBS patients in the absence of contraindications. The gene discussed is GCG; the disease is macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.